Celldex Therapeutics, Inc. — Director's Dealing 2021

Dec 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-12-23

Reporting Person: Martin Samuel Bates (SVP and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-23	Common Stock	M	3250	$9.0165	Acquired	30128	Direct
2021-12-23	Common Stock	M	3750	$2.78	Acquired	33878	Direct
2021-12-23	Common Stock	S	9500	$42.00	Disposed	24378	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-23	Incentive Stock Option (Right to Buy)	$9.0165	M	3250	Disposed	2028-06-13	Common Stock (3250)	Direct
2021-12-23	Incentive Stock Option (Right to Buy)	$2.78	M	3750	Disposed	2029-06-19	Common Stock (3750)	Direct

Footnotes

F1: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.

F2: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

F3: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.